Magnetic resonance imaging has an advantage over conventional spine X-rays in the evaluation of rebound-associated vertebral fractures following denosumab discontinuation.
Denosumab
Discontinuation
Fracture
Osteoporosis
Rebound
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
29
03
2020
accepted:
25
04
2020
pubmed:
23
5
2020
medline:
22
6
2021
entrez:
23
5
2020
Statut:
ppublish
Résumé
Patients discontinuing or neglecting denosumab treatment are at risk of sustaining rebound-associated vertebral fractures (RAVFs). In everyday clinical practice, conventional X-rays are used to diagnose such events in patients reporting acute back pain. Herein we report the cases of two patients, in whom magnetic resonance imaging (MRI) depicted more RAVFs or allowed earlier detection of RAVFs compared with conventional X-rays. It seems that, in the setting of RAVFs following denosumab discontinuation, MRI imaging provides better accuracy in the diagnostic process and in the classification assessment compared to conventional X-rays, thus allowing an earlier and clearer picture of the magnitude of spinal damage. This could have an impact on clinical decisions and improve patient's management.
Identifiants
pubmed: 32441026
doi: 10.1007/s12020-020-02333-1
pii: 10.1007/s12020-020-02333-1
doi:
Substances chimiques
Bone Density Conservation Agents
0
Denosumab
4EQZ6YO2HI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
516-518Références
H.K. Genant, C.Y. Wu, C. van Kuijk, M.C. Nevitt, Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8, 1137–48 (1993)
doi: 10.1002/jbmr.5650080915
F. Grados, C. Roux, M.C. de Vernejoul, G. Utard, J.L. Sebert, P. Fardellone, Comparison of four morphometric definitions and a semiquantitative consensus reading for assessing prevalent vertebral fractures. Osteoporos. Int. 12, 716–22 (2001)
doi: 10.1007/s001980170046
G. Marongiu, S. Congia, M. Verona, M. Lombardo, D. Podda, A. Capone, The impact of magnetic resonance imaging in the diagnostic and classification process of osteoporotic vertebral fractures. Injury 49(Suppl 3), S26–S31 (2018)
doi: 10.1016/j.injury.2018.10.006
U.J. Spiegl, R. Beisse, S. Hauck, A. Grillhosl, V. Buhren, Value of MRI imaging prior to a kyphoplasty for osteoporotic insufficiency fractures. Eur. Spine J. 18, 1287–92 (2009)
doi: 10.1007/s00586-009-1045-2
A.D. Anastasilakis, S.A. Polyzos, P. Makras, Therapy of endocrine disease: denosumab vs. bisphosphonates for the treatment of postmenopausal osteoporosis. Eur. J. Endocrinol. 179, R31–R45 (2018)
doi: 10.1530/EJE-18-0056
H.G. Bone, R.B. Wagman, M.L. Brandi, J.P. Brown, R. Chapurlat, S.R. Cummings, E. Czerwinski, A. Fahrleitner-Pammer, D.L. Kendler, K. Lippuner, J.Y. Reginster, C. Roux, J. Malouf, M.N. Bradley, N.S. Daizadeh, A. Wang, P. Dakin, N. Pannacciulli, D.W. Dempster, S. Papapoulos, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5, 513–523 (2017)
doi: 10.1016/S2213-8587(17)30138-9
A.D. Anastasilakis, M.P. Yavropoulou, P. Makras, G.T. Sakellariou, F. Papadopoulou, S. Gerou, S.E. Papapoulos, Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur. J. Endocrinol. 176, 677–683 (2017)
doi: 10.1530/EJE-16-1027
A.D. Anastasilakis, S.A. Polyzos, P. Makras, B. Aubry-Rozier, S. Kaouri, O. Lamy, Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J. Bone Miner. Res. 32, 1291–1296 (2017)
doi: 10.1002/jbmr.3110
S.R. Cummings, S. Ferrari, R. Eastell, N. Gilchrist, J.B. Jensen, M. McClung, C. Roux, O. Torring, I. Valter, A.T. Wang, J.P. Brown, Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J. Bone Miner. Res. 33, 190–198 (2018)
doi: 10.1002/jbmr.3337
A.D. Anastasilakis, S.E. Papapoulos, S.A. Polyzos, N.M. Appelman-Dijkstra, P. Makras, Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. a prospective 2-year clinical trial. J. Bone Miner. Res. 34, 2220–2228 (2019)
doi: 10.1002/jbmr.3853
M.R. McClung, R.B. Wagman, P.D. Miller, A. Wang, E.M. Lewiecki, Observations following discontinuation of long-term denosumab therapy. Osteoporos. Int. 28, 1723–1732 (2017)
doi: 10.1007/s00198-017-3919-1
J. Leroux, P.H. Vivier, M. Ould Slimane, E. Foulongne, S. Abu-Amara, J. Lechevallier, J. Griffet, Early diagnosis of thoracolumbar spine fractures in children. A prospective study. Orthop. Traumatol. Surg. Res. 99, 60–65 (2013)
doi: 10.1016/j.otsr.2012.10.009
R. Niimi, T. Kono, A. Nishihara, M. Hasegawa, T. Kono, A. Sudo, Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis. Osteoporos. Int. 29, 769–772 (2018)
doi: 10.1007/s00198-017-4334-3
A.W. Popp, P.K. Zysset, K. Lippuner, Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos. Int. 27, 1917–1921 (2016)
doi: 10.1007/s00198-015-3458-6
K.M. Qasem, A. Suzuki, K. Yamada, M. Hoshino, T. Tsujio, S. Takahashi, H. Nakamura, Discriminating imaging findings of acute osteoporotic vertebral fracture: a prospective multicenter cohort study. J. Orthop. Sur. Res 9, 96 (2014)
doi: 10.1186/s13018-014-0096-1